Nanosecond pulsed field ablation for small papillary thyroid cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will use the CellFX nsPFA Percutaneous Electrode System to deliver ultrasound-guided nanosecond pulsed field ablation to T1N0M0 papillary thyroid carcinomas measuring ≤1.5 cm. The primary outcomes are changes in nodule volume, including volume reduction rate, technique efficacy, and nodule regrowth assessed by serial ultrasound. Secondary outcomes include procedure safety and complications, evolving ultrasound features of the treated nodules, and patient-reported health-related quality of life over time. Eligible participants must have Bethesda V or VI cytology, normal labs, no extrathyroidal extension or regional/distant metastases, and agree to scheduled follow-up at the treating center.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant must provide voluntary, written informed consent to participate in this clinical investigation.
* Participant agrees to comply with all study procedures, including all follow-up visits.
* Participant with a Bethesda VI cytology (tumor size \<= 1.5 cm, no known regional/distant metastases)
* Participant with a Bethesda V cytology and normal calcitonin levels.
* Ultrasonographic evaluation of tumor to be ablated must show size of less than or equal to 1.5 cm and no extrathyroidal extension or locoregional metastases.
* Participant must have normal complete blood count, blood coagulation profile, and thyroid function test.
* For females of childbearing potential, a negative serum or urine pregnancy test must be obtained at baseline, prior to the procedure.
* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following: ). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:

  * Postmenopausal (no menses in greater than or equal to 12 consecutive months).
  * History of hysterectomy or bilateral salpingo-oophorectomy.
  * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
  * History of bilateral tubal ligation or another surgical sterilization procedure.
* Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
* Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study procedure.

Exclusion Criteria:

* FNA findings suggestive of high-grade malignancy
* Presence of regional or distant lymph node metastases.
* Participant had a history of previous neck irradiation.
* Females who are pregnant at time of enrollment.
* Participant has any condition or situation, in the opinion of the site Investigator, that puts the subject at significant risk, could confound the study results, or may interfere significantly with subject's participation in the study.

Where it's running

• Sarasota Memorial Hospital
  Sarasota, Florida, United States Recruiting
• The University of Texas M. D. Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Victoria E Banuchi, MPH — M.D. Anderson Cancer Center
• Study coordinator: Victoria E Banuchi, MPH
• Email: vebanuchi@mdanderson.org
• Phone: 713-563-7600

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Thyroid cancer risk and follow-up after childhood radiotherapy

  This project will test whether earlier and regular ultrasound plus genetic testing can detect thyroid nodules and cancers sooner in children treated with radiotherapy.

  Recruiting at 2 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna and 1 other locations · NCT07473518

• Laryngopharyngeal injuries after breathing tube placement during general anesthesia

  This project sees how often and why people who had a breathing tube during general anesthesia developed hoarseness or other throat problems after non-ear–nose–throat surgery.

  Recruiting Zhejiang University · Hangzhou, Zhejiang and 1 other locations · NCT07359586

• International registry for very rare childhood tumors

  This project will collect detailed medical information to see how clinical and biological features affect outcomes in children and adolescents with very rare tumors.

  Recruiting Azienda Ospedaliera di Padova · Padova, Italy · NCT07072143

• Electrical stimulation after thyroid surgery to help with pain

  This trial tests whether a non-drug electrical stimulation method (TENS-WAA) can reduce pain after thyroid surgery compared with a sham treatment.

  Recruiting at 3 sites First Affiliated Hospital of the Chinese People's Liberation Army Naval Medical University · Shanghai, Changning District and 2 other locations · NCT06931743

• Evaluating blood biomarkers in advanced thyroid cancer

  This study is testing if analyzing blood samples from adults with advanced thyroid cancer can help doctors choose better treatments and track how well they work.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna · NCT06863805

• Evaluating diagnostic and therapeutic strategies for thyroid conditions

  This study is testing different ways to diagnose and treat thyroid problems, like hypothyroidism and thyroid cancer, to see which methods work best for patients.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna · NCT06779747

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.